Relationship between p14ARF nuclear overexpression and overall survival
| Variable . | N . | Deaths . | % Survival (60 months) . | Crude analysis . | Adjusted by IPI and histology . | ||||
|---|---|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | ||||
| p14ARF | |||||||||
| Nonnucleoplasmic | 41 | 16 | 59 | 1.00 | 1.00 | ||||
| Nucleoplasmic | 9 | 6 | 28 | 2.47 | 0.96-6.32 | .060 | 2.65 | 1.03-6.83 | .043 |
| IPI | |||||||||
| 0 to 1 | 15 | 1 | 93 | 1.00 | 1.00 | ||||
| 2 | 14 | 7 | 43 | 12.17 | 1.49-99.3 | .020 | 11.65 | 1.43-95.1 | .022 |
| 3 | 10 | 6 | 34 | 13.88 | 1.67-116 | .015 | 12.69 | 1.51-106 | .019 |
| 4 to 5 | 11 | 8 | 27 | 20.40 | 2.53-164 | .005 | 19.12 | 2.36-155 | .006 |
| Histology | |||||||||
| Non-Burkitt | 38 | 19 | 48 | 1.00 | 1.00 | ||||
| Burkitt | 12 | 3 | 73 | 0.43 | 0.13-1.47 | .180 | 0.56 | 0.17-1.90 | .352 |
| Variable . | N . | Deaths . | % Survival (60 months) . | Crude analysis . | Adjusted by IPI and histology . | ||||
|---|---|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | ||||
| p14ARF | |||||||||
| Nonnucleoplasmic | 41 | 16 | 59 | 1.00 | 1.00 | ||||
| Nucleoplasmic | 9 | 6 | 28 | 2.47 | 0.96-6.32 | .060 | 2.65 | 1.03-6.83 | .043 |
| IPI | |||||||||
| 0 to 1 | 15 | 1 | 93 | 1.00 | 1.00 | ||||
| 2 | 14 | 7 | 43 | 12.17 | 1.49-99.3 | .020 | 11.65 | 1.43-95.1 | .022 |
| 3 | 10 | 6 | 34 | 13.88 | 1.67-116 | .015 | 12.69 | 1.51-106 | .019 |
| 4 to 5 | 11 | 8 | 27 | 20.40 | 2.53-164 | .005 | 19.12 | 2.36-155 | .006 |
| Histology | |||||||||
| Non-Burkitt | 38 | 19 | 48 | 1.00 | 1.00 | ||||
| Burkitt | 12 | 3 | 73 | 0.43 | 0.13-1.47 | .180 | 0.56 | 0.17-1.90 | .352 |
N indicates number of patients; HR, hazard ratio; CI, confidence interval.